Zoledronic Acid for Bone Metastases From Breast Cancer (6979) A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid (Zometa) (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Breast Cancer.

Trial Profile

Zoledronic Acid for Bone Metastases From Breast Cancer (6979) A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid (Zometa) (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Breast Cancer.

Not stated
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2012

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top